UCLA Department of Urology Faculty Information

	UROLOGY MAIN SITE	GEN. ADULT UROLOGY	UROLOGIC ONCOLOGY	MALE UROLOGY	TRANSPLANT PROGRAM
	PELVIC MEDICINE, INCONTINENCE & RECONST. SURGERY		PEDIATRIC UROLOGY	MIN. INVASIVE SURGERY

Innovations & Technology

Research & Clinical
Trials

Facilities & Directions

How You Can Help

Department of
Urology Intranet

Allan Pantuck, MD, MS, FACS
a Curriculum Vitae

Allan Pantuck, MD, MS, FACS

Associate Professor of Urology

Location:	66-124 CHS
	Los Angeles, CA 90095
Phone:	310-206-2436

Educational Background

Undergraduate:

BA, Columbia University

Medical School:

M.S., UCLA School of Medicine Master's Degree in Clinical Investigation, Los Angeles
M.D., University of Medicine and Dentistry of New Jersey, Robert Wood Johnson
Medical School, Piscataway, NJ

Residency:

General Surgery and Urology Residencies, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ

Board
Certifications
& Fellowships:

Fellowship in Urologic Oncology, Department of Urology, UCLA School of Medicine

Fellowship in Translational Investigation, UCLA School of Medicine

Diplomate, National Board of Medical Examiners

Specialties

Urologic Oncology

Professional Memberships

American Association for Cancer Research
Fellow, American College of Surgeons
American Society of Clinical Oncology
American Urological Association
International Churchill Society
Western Section American Urological Association
Member, Southwest Oncology Group (SWOG)
Member, Jonsson Comprehensive Cancer Center
Member, UCLA Center for Integrative Medicine
International Society for Biological Therapy of Cancer
Member, Society of Urologic Oncology

Academic & Medical Staff Appointments

2005 to present - Associate Professor of Urology, UCLA Department of Urology
2002- Assistant Professor, UCLA Department of Urology
2001-02 Visiting Assistant Professor, UCLA Department of Urology
1999-01 Clinical Instructor, UCLA Department of Urology.

Research & Clinical Interests

Molecular profiling of kidney cancer. Cancer prevention. Nutrition and cancer. Gene and immune therapies. Molecular imaging. Alternative/complementary medicine and cancer

Awards & Honors

2004 Second place, Miley B. Wesson Essay Contest, Western Section American Urological Association, San Diego, CA, senior author.
2003 Second Place, American Urological Association/ACMI clinical essay contest, 4th
author
2003 Third Place, AUA/ACMI clinical essay contest, 3rd author
2002 Second Prize, Joseph F. McCarthy essay contest, Western Section American Urological Association, 2nd author.
2002 American Society of Clinical Oncology Merit Award, 1st author.
2002 American Society of Clinical Oncology Merit Award, 2nd author.
2001 American Society of Clinical Oncology Merit Award, 2nd author.
1999 Pfizer Scholars in Urology Award.
1998 Third Prize, Basic Science Category, The Philadelphia Urological Society Residents Competition,.
1997 Pfizer Scholars in Urology Award.
1993 Gallo Award, Clinical Oncology, Cancer Institute of New Jersey, Scientific Retreat.
1991 Second prize, Clinical Research, American Urological Association Prize Essay Contest

Personal

Philosophy of Care:

To prevent, cure and improve the quality of my patients' lives. I individualize treatment options for them.

Why I entered Medicine:

I always had an interest in science and I was around a lot of medical people in my family since my father and grandfather were doctors. One of my father's interests was diet and the effect in anesthesiology.

*Additional Information*

Grants and Research Support

2002-2006 NIH K23 Research Career Development Award: Genetic

                 and Molecular Characterization of kidney cancer. $540,000 (PI: Pantuck)

2002-2007 NIH RFA: Chemoprevention of Superficial Bladder Cancer. $7,466,331

                  (PI: Belldegrun)

2004-2008   US Army/DoD IDEA Grant. A Novel Assay of Citrate, Choline, and

                  Spermine in Prostate Cancer $375,000(PI Thomas)

2005-2007   Randomized, double blind, placebo controlled phase III study of

                  pomegranate juice (Pom Wonderful) for men with rising PSA following

                  surgery or radiation. $490,750 (PI Pantuck)

2004-2005: Pom-Wonderful: Estrogenic activity of pomegranate seeds $15,525. (PI:

                 Pantuck)

2004-2006: Phase I: Phase I study of adenovirus GM-CSF-CA IX modified autologous

                 dendritic cells for metastatic kidney cancer. $250,000. (Co-PI: Pantuck)

2003-2004: Amgen Corporation: Protein Biomarker evaluation of Renal Cell

                 Carcinoma. $109,000. (PI: Pantuck)

2002-2003 Xcyte: A Phase I Safety Study of Xcellerate in Patients with Hormone

                 Refractory Prostate Cancer. $113,533 (PI: Pantuck)

2002-2204 Transgene: Randomized Multicenter Phase II Study Evaluating Two

                Dosing Schedules of TG4010 (MVA-MUC1-Il2) in Patients with

                Adenocarcinoma of the Prostate (TG4010.03). $101,299. (PI: Pantuck)

2002-2004: Pom-Wonderful: Pomegranate juice to stop or slow the progression of

                 prostate cancer in men with rising PSA after failed primary therapy.

                 $347,000. (PI: Pantuck)

2002-2004: Chiron Corp. Pilot study of ability of IL-2 to clear circulating tumor cells in

                 patients with metastatic renal cell carcinoma.$57,000(PI:Pantuck).

2002-2005:   Department of Defense. Molecular Characterization of Androgen

                  Independence to Delay Progression to Hormone Refractory Prostate

                  Cancer. $572,000. (PI: Belldegrun).

2001-2003    Ortho-Biotech Perioperative recombinant human erythropoietin for select

                  patients undergoing radical nephrectomy followed by an FDA approved

                  schedule of Interleukin-2 Immunotherapy. Protocol PR00-28-042.

                  $185,000. (PI: Pantuck)

2001-2002: EMD Pharmaceuticals. High Throughput analysis using tissue

                  microarrays to determine the expression of KS antigen in normal kidney,

                  primary renal cell carcinoma, and metastatic renal cell carcinoma.

                  $137,000 (PI:Pantuck)

2001-2003: MD Anderson Cancer Center/Charles Dana Foundation. The effect of

                 psychosocial factors on survival in patients with metastatic renal cell

                 carcinoma. $30,000. (UCLA PI: Pantuck).

2001-2002: Robert Winston Seed Money for Complementary Medicine Research.

                 $100,000 (Co-PI: Pantuck).

1999-2002: NIH K12 National Research Service Award Cancer Gene Medicine

                 Training Program. Total funding $175,000. (PI: Economou).

1990:            American Foundation for Urologic Disease Summer Student Research

                 Fellowship. Medicine Training Program.  (PI: Economou).

P SELECTED PUBLICATIONS:

1. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Fujioka T, Mori M, Kim W, Song J, Pantuck AJ: Comparison of percent equol producer between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean, and American residents. Japanese Journal of Clinical Oncology, 34:86-69,2004.

2. Pantuck AJ, Gitlitz B, van Ophoven A, Tso C, Acres B, Ross M, Belldegrun A, Figlin R: Phase I Trial of a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in Advanced Prostate Cancer: Immunologic modulation mediated Therapeutic Response. Journal of Immunotherapy, 27:240-253, 2004.

3. Seligson D, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui M, Han K, Correa A, Eeva M, Tze S, Palotie A, Figlin R, Belldegrun AS: EpCAM (KSA) is an independent predictor of survival in renal cell carcinoma. Clinical Cancer Research, 10:2659-2669, 2004.

4. Han K, Kim H, Pantuck AJ, Dorey F, Figlin R, Belldegrun AS: The use of the American Society of Anesthesiologists Score to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology, 63:841-846, 2004.

5. Jean-Jacques Patard, Oleg Shvarts, Allan J Pantuck, Hyung L Kim, Vincenzo Ficarra, Luca Cindolo, Ken-ryu Han, Alexandre De La Taille, Jacques Tostain, Walter Artibani, Claude C Abbou, Bernard Lobel, Dominique K Chopin, Robert A Figlin, Peter FA Mulders, Arie S Belldegrun: Safety and Efficacy of Partial Nephrectomy for all T1 Tumors Based on an International Multicenter Experience. Journal of Urology, 171:2181-2185, 2004.

6. Pantuck AJ: Review of Contemporary Management of Prostate Cancer with Lethal Potential. Oncology, 18:820-828, 2004.

7. Lam J, Shvarts O, Pantuck AJ: Changing Concepts in the Surgical Management of Renal Cell Carcinoma. European Urology, 45:692-705, 2004.

8. Jean-Jacques Patard, Hyung L Kim, Frederick Dorey, Allan J Pantuck, Amnon Zisman, Luca Cindolo, Ken-ryu Han, Vincenzo Ficarra, Alexandre De La Taille, Jacques Tostain, Walter Artibani, Colin P Dinney, Christopher G Wood, David A Swanson, Claude C Abbou, Bernard Lobel, Robert A Figlin, Peter FA Mulders, Dominique K Chopin, Arie S Belldegrun: The value of the UISS (UCLA integrated staging system) in predicting survival in renal cell carcinoma: an international study in 4202 patients. Journal of Clinical Oncology, 15;22(16):3316-22, 2004.

9. Han K, Janzen N, McWhorter V, Kim H, Pantuck AJ, Zisman A, Figlin R, Said J, Belldegrun AS: Cystic renal cell carcinoma: biology and clinical behavior. Urologic Oncology, 22:410-414, 2004.

10. Jean-Jacques Patard, Frederick J Dorey, Oleg Shvarts, Luca Cindolo, Vincenzo Ficarra, Alexandre De La Taille, Jacques Tostain, Walter Artibani, Claude C Abbou, Bernard Lobel, François Guillé, Dominique K Chopin, Robert A Figlin, Peter FA Mulders, Arie S Belldegrun, Allan J Pantuck. Symptoms as well as tumor size provide prognostic informationon patients with. Journal of Urology, 172:2167-2171, 2004.

11. Zeng G, Aldridge M, Wang Y, Pantuck AJ, Wang A, Liu Y, Han Y, Yuan Y, Robbins P, Dubinett S, deKernion JB, and Belldegrun AS: A Dominant B Cell Epitope from NY-ESO-1 Recognized by Sera from a Wide Spectrum of Cancer Patients: Implications as a Potential Biomarker.

12. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin RA, Belldegrun A, Pantuck AJ: p53 is an independent predictor of tumor recurrence and progression after nephrectomy for patients with localized renal cell carcinoma. Journal of Urology, 173:725-728, 2005.

13. Lam J, Pantuck AJ, Belldegrun A, Figlin R: G250: A Carbonic Anhydrase IX Monoclonal Antibody. Current Oncology Reports 7:109-15, 2005.

14. Lu Q, Jin Y, Pantuck A, Zhang ZF, Heber D, Belldegrun A, Brooks M, and Rao J: Green Tea Extract Modulates Actin Remodeling in an in vitro Multistep Carcinogenic Model via Rho Activity. Clinical Cancer Research, 11(4):1675-83, 2005.

15. Jean-Jacques Patard, Nathalie Rioux-Leclercq, Luca Cindolo, Vincenzo Ficarra, Ken-ryu Han, Alexandre De La Taille, Jacques Tostain, Walter Artibani, Claude C Abbou, Bernard Lobel, Guillé François, Rioux-Leclercq Nathalie, Dominique K Chopin, Peter FA Mulders, Christopher G Wood, Robert A Figlin, Arie S Belldegrun and Allan J Pantuck. The prognostic value of histologic subtypes in Renal Cell Carcinoma (RCC). A multicenter experience in 4063 patients. Journal of Clinical Oncology, 23(12):2763-71, 2005.

16. Shvarts O, Said J, Lam J, Pantuck AJ, Seligson D, Aldridge M, Bui M, Liu X, Horvath S, Belldegrun A: Clinical, pathological, and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer, 103:2517-2525, 2005.

17. Shvarts O, Lam J, Pantuck AJ, Figlin R, and Belldegrun A: Postoperative Surveillance Protocol for Patients with Localized and Locally Advanced Renal Cell Carcinoma Based on a Validated Prognostic Nomogram and Risk Group Sratification System. Journal of Urology, 174:466-472, 2005.

18. Leppert JT, Lam JS, Pantuck AJ, Figlin RA and Belldegrun AS: Carbonic Anhydrase IX and the Future of Molecular Markers in Renal Cell Carcinoma. BJU Int, Aug;96(3):281-5, 2005.

19. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken W, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann T: Gene Signatures of Progression and Metastasis in Renal Cell Cancer. Clin Cancer Res, Aug 15;11(16):5730-9, 2005.

20. Mestas J, Burdick M, Reckamp K, Pantuck AJ, Figlin RA, Strieter RM: The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. Journal of Immunotherapy, 175:5351-5357, 2005.

21. Cao W, Cai L, Rao J, Pantuck A, Lu ML, Dalbagni G, Reuter V, Scher H, Cordon-Card